Iclusig and Agranulocytosis - a phase IV clinical study of FDA data
Agranulocytosis is found among people who take Iclusig, especially for people who are male, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Iclusig and have Agranulocytosis. It is created by eHealthMe based on reports of 5,508 people who have side effects when taking Iclusig from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
5,508 people reported to have side effects when taking Iclusig.
Among them, 139 people (2.52%) have Agranulocytosis.
What is Iclusig?
Iclusig has active ingredients of ponatinib hydrochloride. eHealthMe is studying from 5,509 Iclusig users for its effectiveness, alternative drugs and more.
What is Agranulocytosis?
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 3,082 drugs and 3,325 conditions by eHealthMe.
Number of Iclusig and Agranulocytosis reports submitted per year:
Time on Iclusig when people have Agranulocytosis *:
Gender of people who have Agranulocytosis when taking Iclusig*:
Age of people who have Agranulocytosis when taking Iclusig *:
Common drugs people take besides Iclusig *:
Common side effects people have besides Agranulocytosis *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Iclusig and have Agranulocytosis?Check whether Agranulocytosis is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
How severe was Agranulocytosis and when was it recovered:
Expand to all the drugs that have ingredients of ponatinib hydrochloride:
Alternative drugs to, pros and cons of Iclusig:
- Iclusig (5,509 reports)
Common Iclusig side effects:
Browse all side effects of Iclusig:a b c d e f g h i j k l m n o p q r s t u v w x y z
Agranulocytosis treatments and more:
- Agranulocytosis (180,977 reports)
COVID vaccines that are related to Agranulocytosis:
- Agranulocytosis in Moderna COVID Vaccine
- Agranulocytosis in Pfizer BioNTech Covid Vaccine
- Agranulocytosis in Johnson and Johnson Covid Vaccine
Common drugs associated with Agranulocytosis:
All the drugs that are associated with Agranulocytosis:
- Agranulocytosis (3,082 drugs)
Common conditions associated with Agranulocytosis:
All the conditions that are associated with Agranulocytosis:
- Agranulocytosis (3,325 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on ponatinib hydrochloride (the active ingredients of Iclusig) and Iclusig (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Aventyl and Concerta drug interaction - 9 seconds ago
- Ginger and Psoriasis - 39 seconds ago
- Magnesium and Levaquin drug interaction - 46 seconds ago
- Qvar 40 and Crestor drug interaction - 52 seconds ago
- Nasal Congestion and Sinusitis - Acute - a minute ago
- Nasal Congestion and Sinusitis - a minute ago
- Acute Lymphocytic Leukemia (All) and Abortion Spontaneous - a minute ago
- Lotrel and Aleve drug interaction - a minute ago
- Profenal and Jaundice - Yellow Skin - a minute ago
- Vitamin C and Purinethol drug interaction - a minute ago